Overview

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Response Rate
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Bristol-Myers Squibb
Celgene
Rhone-Poulenc Rorer
Rising Tide Foundation
Stand Up To Cancer
Syndax Pharmaceuticals, Inc.
Treatments:
Antibodies, Monoclonal
Azacitidine
Entinostat
Nivolumab